Navigation Links
LifeVantage Announces Preliminary Third Quarter 2011 Revenue
Date:4/14/2011

SAN DIEGO, April 14, 2011 /PRNewswire/ -- LifeVantage Corporation (OTCBB: LFVN), the maker of science-based solutions to oxidative stress, announced preliminary net revenue for its third fiscal quarter of 2011 of approximately $10 million. This represents an increase of approximately $2.6 million or 35% over net revenue of $7.4 million for the three month period ended December 31, 2010. This is also an approximate $7.3 million or 270% increase in net revenue over the $2.7 million net revenue reported for the same quarter last year.

(Logo:  http://photos.prnewswire.com/prnh/20090930/LIFEVANTAGELOGO)

"We are so excited to be holding our first annual international Convention April 14th – 16th, and to be able to announce such impressive revenue growth.  As we continue to finalize our results, we also anticipate reporting our highest quarterly operating profit to date," stated Douglas C. Robinson, President & Chief Executive Officer of LifeVantage.  

About LifeVantage Corporation

LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, nutraceutical company dedicated to helping people reach their health and wellness goals while creating business opportunities. Founded in 2003 and based in San Diego, CA, LifeVantage currently offers two anti-aging and wellness products: Protandim®, a dietary supplement that combats oxidative stress, and LifeVantage TrueScience™ Anti-Aging Cream, a scientifically-based skin care product. For more information, visit www.LifeVantage.com.

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements can be identified by words such as 'believes,' 'anticipates,' 'intends,' 'plans,' 'seeks' and similar references to the future.  Examples of forward-looking statements include, but are not limited to, statements we make regarding our anticipated results of operations and future growth. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the risk factors contained in the Company's Annual Report on Form 10-K and its Quarterly Report on Form 10-Q under the caption "Risk Factors", and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

Investor Relations Contact:
Ioana C. Hone
(858) 312-8000 Ext. 4


'/>"/>
SOURCE LifeVantage Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. LifeVantage Announces Settlement of Zrii Litigation
2. LifeVantage Announces Unaudited First Quarter Fiscal 2010 Financial and Operating Results
3. LifeVantage Announces Preliminary Unaudited First Quarter Revenue
4. LifeVantage Announces Fourth Quarter and Fiscal Year 2009 Financial and Operating Results
5. Beacon Announces Agreement With New Fortune 500 Pharmaceutical Client
6. IDEV Announces Full Canadian Regulatory Approval for SUPERA VERITAS®
7. Solta Medical Announces First Quarter 2011 Results Release and Conference Call
8. Amgen Announces Webcast of 2011 First Quarter Financial Results
9. Award Winning Vascular Imaging Device Company Announces New Patents
10. ThermoGenesis Announces Registration of Res-Q in India; Commercial Sales Expected to Begin in Current Quarter
11. Medco Announces Date for Release of First-Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):